PreserFlo MicroShunt® exposure: a case series.
InnFocus
MIGS
Microshunt
PreserFlo
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
10 Jul 2021
10 Jul 2021
Historique:
received:
26
06
2020
accepted:
01
07
2021
entrez:
11
7
2021
pubmed:
12
7
2021
medline:
14
7
2021
Statut:
epublish
Résumé
PreserFlo® MicroShunt (PM) (also known as InnFocus® MicroShunt) is a subconjunctival stent implanted ab externo via a minimally invasive surgical procedure. The current indication is progressive, mild to moderate, open angle glaucoma uncontrolled on topical medications. According to the literature, adverse events are rare, mild and transient. Two cases of stand-alone PreserFlo MicroShunt® implantation in patients with uncontrolled open-angle glaucoma are reported. Exposure occurred 7 days and 3 months respectively after implantation. These cases shared common features including preexisting blepharitis and the lack of a Tenon's flap. In both cases, removal of the device was required after several attempts at repair. PreserFlo MicroShunt® exposure is a potentially vision-threatening complication because of the risk of endophthalmitis. Potential risk factors include the absence of a Tenon's flap and pre-existing ocular surface inflammation. Ocular surface inflammation should be detected and treated prior to PM implantation. If a deficiency in Tenon's capsule is noted intraoperatively, close monitoring should be performed because of the higher risk of PM exposure.
Sections du résumé
BACKGROUND
BACKGROUND
PreserFlo® MicroShunt (PM) (also known as InnFocus® MicroShunt) is a subconjunctival stent implanted ab externo via a minimally invasive surgical procedure. The current indication is progressive, mild to moderate, open angle glaucoma uncontrolled on topical medications. According to the literature, adverse events are rare, mild and transient.
CASE PRESENTATION
METHODS
Two cases of stand-alone PreserFlo MicroShunt® implantation in patients with uncontrolled open-angle glaucoma are reported. Exposure occurred 7 days and 3 months respectively after implantation. These cases shared common features including preexisting blepharitis and the lack of a Tenon's flap. In both cases, removal of the device was required after several attempts at repair.
CONCLUSIONS
CONCLUSIONS
PreserFlo MicroShunt® exposure is a potentially vision-threatening complication because of the risk of endophthalmitis. Potential risk factors include the absence of a Tenon's flap and pre-existing ocular surface inflammation. Ocular surface inflammation should be detected and treated prior to PM implantation. If a deficiency in Tenon's capsule is noted intraoperatively, close monitoring should be performed because of the higher risk of PM exposure.
Identifiants
pubmed: 34246229
doi: 10.1186/s12886-021-02032-z
pii: 10.1186/s12886-021-02032-z
pmc: PMC8272321
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Informations de copyright
© 2021. The Author(s).
Références
Regen Biomater. 2016 Jun;3(2):137-42
pubmed: 27047682
Clin Ophthalmol. 2020 Jun 30;14:1805-1832
pubmed: 32636610
J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221
pubmed: 26380916
Ophthalmologe. 2020 Dec;117(12):1229-1233
pubmed: 32112220
Jpn J Ophthalmol. 2009 Mar;53(2):114-119
pubmed: 19333694
Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):203-214
pubmed: 32501895
J Cataract Refract Surg. 2014 Aug;40(8):1301-6
pubmed: 24943904
Am J Ophthalmol. 2017 Nov;183:25-36
pubmed: 28784554
J Ophthalmol. 2013;2013:196215
pubmed: 23970955
Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):765-771
pubmed: 29356886
BMC Ophthalmol. 2019 Dec 12;19(1):253
pubmed: 31830935
J Glaucoma. 2018 Dec;27(12):e191-e194
pubmed: 30180015
Eur J Ophthalmol. 2020 Sep;30(5):1034-1041
pubmed: 31018685
Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):983-996
pubmed: 30758653
Clin Exp Ophthalmol. 2018 May;46(4):339-345
pubmed: 29053204
Int J Ophthalmol. 2019 Apr 18;12(4):689-691
pubmed: 31024828
Arch Soc Esp Oftalmol (Engl Ed). 2018 Feb;93(2):93-96
pubmed: 29224970
J Glaucoma. 2018 Oct;27(10):934-935
pubmed: 30113510
J Glaucoma. 2018 Jan;27(1):e11-e13
pubmed: 29088056
Clin Ophthalmol. 2016 Mar 30;10:547-53
pubmed: 27099461
Ophthalmology. 2017 Nov;124(11):1579-1588
pubmed: 28601250
Ophthalmol Ther. 2019 Sep;8(3):435-446
pubmed: 31197608
J Glaucoma. 2019 Mar;28(3):e37-e40
pubmed: 30676470
Trans Am Ophthalmol Soc. 2012 Dec;110:40-63
pubmed: 23818734
Clin Exp Optom. 2018 May;101(3):339-344
pubmed: 29232760
J Glaucoma. 2021 Mar 1;30(3):281-286
pubmed: 33137019
J Fr Ophtalmol. 2019 Feb;42(2):e37-e46
pubmed: 30683533
Ophthalmology. 2015 Sep;122(9):1737-9
pubmed: 26299720
Case Rep Ophthalmol Med. 2015;2015:847439
pubmed: 26294994
J Glaucoma. 2019 Jun;28(6):e93-e95
pubmed: 30676411
Am J Ophthalmol. 2020 Jul;215:141-153
pubmed: 32173344
Eye (Lond). 2019 Mar;33(3):469-477
pubmed: 30356133
Prog Retin Eye Res. 2010 Jul;29(4):312-34
pubmed: 20302969
Ophthalmology. 2018 Feb;125(2):209
pubmed: 29389405
Br J Ophthalmol. 2020 Oct 23;:
pubmed: 33097520
Acta Ophthalmol. 2021 May;99(3):e433-e440
pubmed: 32909682
J Glaucoma. 2018 Oct;27(10):931-933
pubmed: 29952822
J Glaucoma. 2016 Feb;25(2):e58-65
pubmed: 26766400
Acta Ophthalmol. 2019 Dec;97(8):e1105-e1111
pubmed: 31210015
Ophthalmology. 1999 Mar;106(3):556-63
pubmed: 10080214
J Ophthalmol. 2017;2017:5457246
pubmed: 28348884
Am J Ophthalmol. 2018 May;189:96-101
pubmed: 29499173